Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.

被引：0
|
作者：
Mamdani, Hirva
Clarke, Jeffrey Melson
Gu, Lin
Stinchcombe, Tom
Crawford, Jeffrey
Antonia, Scott Joseph
Campa, Michael
Nixon, Andrew B.
Sonpavde, Guru P.
Simon, George R.
Ready, Neal E.
Herndon, James E., II
Patz, Edward F.
机构：
[1] Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI USA
[2] Duke Univ, Trent Ctr Bioeth Humanities & & Hist Med, Durham, NC USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Duke Canc Inst, Durham, NC USA
[5] AdventHth Canc Inst, Orlando, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Celebration, FL USA
[7] Duke Univ, Dept Anesthesiol, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14588
引用
收藏
页数：1
相关论文
共 50 条
  • [1] INTERIM RESULTS FROM A PHASE IB, FIRST-IN-HUMAN STUDY OF A NOVEL COMPLEMENT FACTOR H INHIBITOR (GT103) IN PATIENTS WITH REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC)
    Clarke, Jeffrey
    Stinchcombe, Thomas
    Crawford, Jeffrey
    Mamdani, Hirva
    Gu, Lin
    Ready, Neal
    Nixon, Andrew
    Baleviic, Stephen
    Campa, Michael
    Gottlin, Liz
    Bushey, Ryan
    Herndon, James
    Antonia, Scott
    Patz, Edward
    Simon, George
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A730 - A730
  • [2] Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC)
    Clarke, Jeffrey Melson
    Stinchcombe, Tom
    Gu, Lin
    Mamdani, Hirva
    Antonia, Scott Joseph
    Simon, George R.
    Sonpavde, Guru P.
    Ready, Neal E.
    Crawford, Jeffrey
    Campa, Michael
    Gottlin, Elizabeth
    Bushey, Ryan
    Herndon, James Emmett
    Patz, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial
    Clarke, Jeffrey M.
    Simon, George R.
    Mamdani, Hirva
    Gu, Lin
    Herndon II, James E.
    Stinchcombe, Thomas E.
    Ready, Neal
    Crawford, Jeffrey
    Sonpavde, Guru
    Balevic, Stephen
    Nixon, Andrew B.
    Campa, Michael
    Gottlin, Elizabeth B.
    Li, Huihua
    Saxena, Ruchi
    He, You Wen
    Antonia, Scott
    Patz Jr, Edward F.
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [4] Modulation of autophagy with hydroxychloroquine in patients with advanced non-small cell lung cancer (NSCLC): A phase Ib study.
    Malhotra, Jyoti
    Jabbour, Salma
    Orlick, Michelle
    Riedlinger, Gregory
    Joshi, Sonali
    Guo, Jessie Yanxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] IMMUNOGENICITY AND SAFETY OF THE PRAME CANCER IMMUNOTHERAPEUTIC IN NON-SMALL CELL LUNG CANCER (NSCLC): PHASE I DOSE ESCALATION STUDY
    Pujol, J.
    De Pas, T.
    Rittmeyer, A.
    Kubisa, B.
    Vallieres, E.
    Levchenko, E.
    Salaun, B.
    Vanhoutte, N.
    Debois, M.
    Brichard, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 386 - 386
  • [6] Preliminary results from phase Ib study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Santoro, A.
    Garrido Lopez, P.
    Tan, D. S. W.
    Paz-Ares, L.
    Shepherd, F.
    Bearz, A.
    Barlesi, F.
    Vansteenkiste, J. F.
    Kim, T. M.
    Overbeck, T. R.
    Rybkin, I. I.
    Felip, E.
    Zhou, W.
    Santarpia, L.
    Eddy, S.
    Schaefer, E. S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study
    Pierre, Clemence
    Le Guen, Yannick
    Giordanengo, Caroline
    Goter, Thomas
    Lena, Herve
    Niel, Clemence
    De Chabot, Gonzague
    Tiercin, Marie
    Le Garff, Gwenaelle
    Zimmermann, Francois
    Le Cornu, Quentin
    Ricordel, Charles
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (08)
  • [8] Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC): Updated results of an ongoing study.
    Read, WL
    Toles, L
    Romvari, E
    Adkins, D
    McLeod, H
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 707S - 707S
  • [9] CONCURRENT CHEMORADIOTHERAPY WITH TOMOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PHASE I, DOSE-ESCALATION STUDY
    Bearz, Alessandra
    Minatel, Emilio
    Abu Rumeileh, Imad
    Gobitti, Carlo
    Baresic, Tanja
    Drigo, Annalisa
    Talamini, Renato
    Vaccher, Emanuela
    Santarossa, Sandra
    Franchin, Gianni
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1553 - S1553
  • [10] A phase I dose escalation study of sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Frickhofen, N.
    Gatzemeier, U.
    Fuhr, H.
    Lanzalone, S.
    Lechuga, M. J.
    Wang, E.
    Chao, R.
    Felip, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345